Granules India reported strong FY26 results, with revenue rising 20% to ₹53,656 Mn. EBITDA grew 25% to ₹11,851 Mn, and PAT increased 19% to ₹5,950 Mn. The company also expanded gross margins to a record 65% and acquired Senn Chemicals AG.

Granules India's Fiscal Year 2026 Performance Review

Revenue: ₹53,656 Mn | EBITDA: ₹11,851 Mn

Reader Takeaway: Record margins and CDMO expansion signal improved business quality; track Gagillapur facility and peptide growth.

What just happened

Granules India reported robust financial results for FY26. Consolidated revenue grew by 20% to ₹53,656 million, while EBITDA saw a significant 25% increase to ₹11,851 million. Profit After Tax (PAT) rose by 19% to ₹5,950 million.

The company achieved a record gross margin of 65% in FY26, an expansion of approximately 1,500 basis points since FY2022, attributed to a strategic shift towards complex and differentiated products.

Why this matters

These results indicate a successful transition for Granules India towards a value-driven, science-led pharmaceutical model. The improved profitability, driven by higher margins and strategic acquisitions, suggests enhanced business quality and potential for sustained growth. The company's disciplined approach to debt management, with a Net Debt to EBITDA ratio of 0.34x, further strengthens its financial position.

The backstory

Granules India has been focusing on evolving its product portfolio. The acquisition of Senn Chemicals AG in Switzerland marks a significant step into the peptide Contract Development and Manufacturing Organisation (CDMO) space, with this new vertical already turning EBITDA positive in Q4 FY26.

What changes now

The company's strategic priorities for FY2027 include completing regulatory processes at the Gagillapur facility, optimizing capacity utilization, continuing its product mix shift, and growing the peptide CDMO platform.

Risks to watch

• Market Concentration: 74% of revenue comes from North America, posing risks related to pricing and regulatory changes in that key market.
• Regulatory Remediation: Elevated expenditures are associated with completing the regulatory journey at the Gagillapur facility.

Peer comparison

Granules India's strategic shift towards complex products and CDMO services places it in a competitive landscape with other pharmaceutical players focusing on niche and high-value offerings. Its strong margin expansion and debt management are key differentiators.

Context metrics (time-bound)

• FY26 Revenue: ₹53,656 Mn (up 20% YoY)
• FY26 EBITDA: ₹11,851 Mn (up 25% YoY)
• FY26 PAT: ₹5,950 Mn (up 19% YoY)
• Gross Margin: 65% (record high)
• Net Debt to EBITDA: 0.34x

What to track next

Investors should closely monitor the progress of the Gagillapur facility's regulatory remediation and the growth trajectory of the peptide CDMO business. Sustaining high gross margins amidst external cost pressures and regulatory requirements will be crucial.